G
This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1 (b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitionist. The North American Industry Classification System code is 541990 and the business size standard is $15.0M.
The purpose of this procurement is to add data to an existing cohort of breast cancer survivors from Kaiser Permanente Washington Health Research Institute (KPWHRI) into the currently existing Kaiser/DCEG Breast Cancer Survivors' Cohort study. The project objectives are to retrieve mammograms for MBD assessment from contralateral breast cancer (CBC) cases and their matched controls, who will be identified from the KPWHRI cohort within the study period (1990-2017). Because tamoxifen, a highly effective treatment of estrogen receptor positive breast cancer, can affect MBD post-treatment, DCEG is also interested in retrieving medications potentially interacting with tamoxifen to better understand their effects in MBD, density changes and risk of CBC among women being treated with tamoxifen.
KPWHRI is an excellent platform to identify risk factors, including MBD, that are associated with CBC, as KPWHRI possesses high quality electronic medical records for large numbers of women diagnosed with breast cancer as well as maintaining breast cancer screening information for all women included in its health care plan. Investigations of CBC are also complicated by treatment received for the first cancer. KPWHRI also provides a suitable platform to overcome these difficulties as detailed prescription records which includes any treatment received following a cancer diagnosis are maintained for all members of KPWHRI.
The overall aims of this procurement are to determine the relationship between MBD, MBD change and risk of developing CBC by retrieving mammograms for CBC cases and matched controls (i.e., women with an index breast carcinoma who have not yet developed CBC but remain at CBC risk) who are selected from the KPWHRI cohort of breast cancer patients.
The unique qualification of KPWHRI to this procurement is access to MBD data from the existing cohort of breast cancers survivors, a population-based cohort from Kaiser Permanente, Seattle, WA, which has been linked with the Seattle SEER registry to identify second cancer incidence and mortality. KPWHRI possesses large numbers of women diagnosed with breast cancer as well as maintaining breast cancer screening information for all women included in its health care plan. They also have access to prescription records which include any treatment received following a cancer diagnosis, and are maintained for all members of KPWHRI, which could affect MBD. For the aforementioned reasons, KPWHRI is the only known source that can fulfill the requirements of this study.
This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a capability statement for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 3:00 PM ET, on February 11, 2019. All responses and questions must be via email to Miguel Diaz, Contracting Officer at [email protected]. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered and have valid certification through SAM.GOV and have Representations and Certifications filled out. Reference: 75N91019Q00024 on all correspondence.